Studying clonal evolution of myeloid malignancies using induced pluripotent stem cells

Purpose of review Myeloid malignancies comprise a spectrum of genetically heterogeneous disorders marked by the stepwise acquisition of somatic mutations and clonal evolution. The blood and bone marrow of patients typically consists of a mix of different clones and subclones along the path of clonal evolution that cannot be deconvoluted with most current approaches. Here, we review the application of induced pluripotent stem cell (iPSC) technology to the study of the clonal architecture and clonal evolution of these diseases, focusing on myelodysplastic syndromes and acute myeloid leukemia. Recent findings Reprogramming to pluripotency allows capture of the genomes of single somatic cells into stable iPSC lines. In addition, precise genome editing can introduce specific driver mutations, isolated, and in combinations, into normal iPSCs. Studies utilizing these approaches have elucidated the clonal composition and mutational order in patients with myeloid neoplasms. Importantly, they have also enabled functional interrogation of the cellular and molecular consequences of individual mutations and their combinations and allowed testing of the effects of drugs on distinct disease clones. Summary Human iPSCs are important tools to elucidate the mechanisms of progression from normal to malignant haematopoiesis and empower drug testing and drug discovery.
Source: Current Opinion in Hematology - Category: Hematology Tags: MYELOID BIOLOGY: Edited by H. Leighton Grimes Source Type: research

Related Links:

Abstract Myelodysplastic syndrome is a heterogenous group of disorder with clonal dysregulated hematopoiesis characterized by bone marrow failure, cytogenetic and molecular abnormalities and variable risk of progression to acute myeloid leukemia (AML). The bone marrow niche plays a major role in maintaining the homeostasis and is often injured by the chemotherapeutic drugs leading to catastrophic consequences like myelodysplastic syndrome. In the present study, we made an attempt to find out the osteoblastic niche related alterations in the myelodysplastic bone marrow through mainly flowcytometric and fluorescent ...
Source: Molecular and Cellular Biochemistry - Category: Biochemistry Authors: Tags: Mol Cell Biochem Source Type: research
Abstract Germline GATA2 heterozygous mutations were identified as complex immunodeficiency and hematological syndromes characterized by cytopenia (monocytes, B-cells, NK-cells), susceptibility to mycobacterium, fungus, or Epstein-Barr virus (EBV) infection, and myelodysplastic syndrome (MDS)/acute myelogenous leukemia (AML) development. Herein, we report a patient with AML who had a fatal infection after allogeneic hematopoietic stem cell transplantation (HSCT) due to impaired immune reconstitution associated with GATA2 mutation. A 15-year-old man was diagnosed with AML with monosomy 7. His family history was nega...
Source: International Journal of Hematology - Category: Hematology Authors: Tags: Int J Hematol Source Type: research
elosi Acute myeloid leukemia (AML) is a heterogeneous disease generated by the acquisition of multiple genetic and epigenetic aberrations which impair the proliferation and differentiation of hematopoietic progenitors and precursors. In the last years, there has been a dramatic improvement in the understanding of the molecular alterations driving cellular signaling and biochemical changes determining the survival advantage, stimulation of proliferation, and impairment of cellular differentiation of leukemic cells. These molecular alterations influence clinical outcomes and provide potential targets for drug development...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
Abstract The tumor suppressor p53 exerts pivotal roles in hematopoietic stem cell (HSC) homeostasis. Mutations of the TP53 gene have recently been described in individuals with clonal hematopoieis conferring substantial risk of developing blood cancers. In patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), TP53 aberrations - mutations, deletions and a combination thereof - are encountered at a constant frequency of approximately 10%. These aberrations affect HSCs transforming them into preleukemic stem cells, pinpointing their central role in leukemogenesis. AML and MDS with TP53 aberr...
Source: Clinical Cancer Research - Category: Cancer & Oncology Authors: Tags: Clin Cancer Res Source Type: research
Kobbe Thomas Schroeder To provide long-term outcome data and predictors for response and survival, we retrospectively analyzed all 151 patients with relapse of myeloid neoplasms after allogeneic hematopoietic stem cell transplantation (allo-HSCT) who were uniformly treated with first-line azacitidine (Aza) salvage therapy at our center. Patients were treated for molecular (39%) or hematologic relapse (61%), with a median of 5 cycles of Aza and at least one donor lymphocyte infusion in 70% of patients. Overall response was 46%, with 41% achieving complete (CR) and 5% achieving partial remission. CR was achieved after ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
AbstractTherapy related acute leukemia consists of a unique subset of acute leukemia with an increased frequency of high risk cytogenetic and molecular abnormalities, dismal response to therapy, higher relapse rates and poor overall survival. Therapy related acute myeloid leukemia (t-AML) is a better defined disease entity than therapy related acute lymphoid leukemia (t-ALL). However, in recent times, t-ALL is also being increasingly recognized and extensively studied. Therapy related acute myeloid leukemia is usually classified together with therapy related myelodysplastic syndrome. However, the management of these two di...
Source: Indian Journal of Hematology and Blood Transfusion - Category: Hematology Source Type: research
Solomon et al [1], reporting for the Center for International Blood and Marrow Transplantation Research (CIBMTR), compare outcomes in African American adults (age 18 to 70 years) with a hematologic malignancy (acute myelogenous leukemia, acute lymphoblastic leukemia, myelodysplastic syndrome, or non-Hodgkin lymphoma) following T cell-replete haploidentical stem cell transplantation (haploSCT) with post- haploSCT cyclophosphamide versus unrelated umbilical cord blood transplantation (UCBT). The UCBT group included both single (>2.5  × 107total nucleated cells [TNCs]/kg) and double (>1.5  × 107 TNCs...
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Tags: Commentary Source Type: research
Patients with MDS are clinically subdivided into lower-risk (very low/low/intermediate risk) and higher-risk (high/very high risk) disease according to the revised International Prognostic Scoring System (IPSS-R) risk score [1,2]. Patients with lower-risk MDS are affected primarily by symptoms of chronic anemia and fatigue [3]. Patients with neutropenia and thrombocytopenia are at increased risk for infection, bleeding, and also progression to acute myelogenous leukemia [2]. In a study of patients with lower-risk MDS, hemoglobin level was the most important independent predictor of health-related quality of life [4].
Source: Biology of Blood and Marrow Transplantation - Category: Hematology Authors: Source Type: research
We compared the transplant outcomes between HID and MSD transplants for AML and MSD aged ≥50 years. The results showed that HID transplant is feasible and safe for elderly AML/MDS patients. AbstractAllogeneic hematopoietic stem cell transplantation (allo ‐HSCT) is a potentially curative therapeutic option for patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Increasing data suggest that haploidentical donor (HID) transplantation achieve comparable outcomes with HLA‐matched sibling donor (MSD) in adult AML/MDS. This re trospective study compared the outcomes of AML or MDS patients age ...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Myeloablative intravenous busulfan-containing regimens for allo-HSCT in AML or MDS patients over 54 years old: combined results of three phase II studies. Int J Hematol. 2020 Jul 12;: Authors: Uchida N, Matsumoto K, Sakura T, Hidaka M, Miyamoto T, Eto T, Maeda Y, Murayama T, Fujishima N, Yoshimoto G, Morita K, Kishimoto J, Teshima T, Taniguchi S, Yamashita T, Mori SI, Akashi K, Harada M, Japan Study Group for Cell Therapy, Transplantation (JSCT) Abstract An optimal pretransplant conditioning regimen for allogeneic hematopoietic stem cell transplantation (allo-HSCT) in older adults has not been es...
Source: International Journal of Hematology - Category: Hematology Authors: Tags: Int J Hematol Source Type: research
More News: Acute Leukemia | Acute Myeloid Leukemia | Biology | Cancer & Oncology | Genetics | Hematology | Leukemia | Mergers and Aquisitions | Molecular Biology | Myelodysplastic Syndrome | Stem Cell Therapy | Stem Cells | Study